The size of the Global Vaccine Contract Manufacturing Market is estimated to worth USD 1363 million by 2025 from USD 915 million in 2020 and is expected to rise at a CAGR of 8.3% during the forecast period.
A vaccine is a biological element prepared to assist the immunity of a person against one or several diseases. Contracted Vaccine manufacturing establishment has higher qualitative and quantitative controlling standards with a significant margin of fixed costs, and production & development linked difficulties, have limited competition between vaccine manufacturers. Moreover, these complications have restricted the vaccine contract manufacturing size to a great extent.
Recent progress in biomanufacturing and biotechnology has led to the development of ground-breaking technologies that are capable of addressing the difficulties related to the manufacture of vaccines. Therefore, there is an increase in Vaccine contract manufacturing market growth. Earlier, the vaccine market was targeted towards preventive vaccines and mass production against infectious diseases. The beginning of therapeutic vaccines has changed interest in this field by paving methods for vaccines to be developed for a diversity of chronic and degenerative ailments, which has promoted the entry of a number of manufacturers and blooming stakeholders who are competing for a market investment in this potential market segment.
REPORT COVERAGE
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2019 to 2025 |
|
Base Year |
2019 |
|
Forecast Period |
2020 to 2025 |
|
Segments Covered |
By Service Type, Product Type, Vaccine Type and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
This research report on the global vaccine contract manufacturing market has been segmented and sub-segmented based on the service type, product type, vaccine type and region.
Vaccine Contract Manufacturing Market - By Service Type
Vaccine Contract Manufacturing Market - By Product Type
Global Vaccine Contract Manufacturing Market – By Vaccine Type
Global Vaccine Contract Manufacturing Market – By Region
Regionally, North America takeovers the global market having the existence of a large number of contract manufacturing organizations (CMOs). About 40 CMOs are present in diverse locations in the U.S. Europe is the next major market for vaccine contract manufacturing with about 20 CMOs located in Germany, U.K, and France. The market in the Asia Pacific is about to expand at a high growth rate throughout the forecast period due to rapidly growing economies of India and China.
NOTEWORTHY COMPANIES IN THE MARKET
Key market leaders operating in the global vaccine contract manufacturing market profiled in this report are Thomas Jefferson University, Goodwin Biotechnology Inc., BioMARK, Emergent BioSolutions, Soligenix Inc., Catalent Biologics, Minneapolis Medical Research Foundation (MMRF), Bavarian Nordic A/S and FUJIFILM Diosynth Biotechnologies
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Service Type
5.1.1 Introduction
5.1.2 Bulk Product
5.1.3 Fill Finish
5.1.4 Y-o-Y Growth Analysis, By Service Type
5.1.5 Market Attractiveness Analysis, By Service Type
5.1.6 Market Share Analysis, By Service Type
5.2 Product Type
5.2.1 Introduction
5.2.2 Single Vaccine
5.2.2.1 Influenza Virus
5.2.2.2 Chicken Pox
5.2.2.3 Ebola Virus
5.2.2.4 Tetanus
5.2.2.5 Tuberculosis
5.2.2.6 Polio
5.2.2.7 Small Pox
5.2.3 Combination Vaccine
5.2.4 Y-o-Y Growth Analysis, By Product Type
5.2.5 Market Attractiveness Analysis, By Product Type
5.2.6 Market Share Analysis, By Product Type
5.3 Vaccine Type
5.3.1 Introduction
5.3.2 Inactivated Vaccines
5.3.3 Conjugate Vaccines
5.3.4 Live Attenuated
5.3.5 Toxoid Vaccines
5.3.6 Recombinant Vector Vaccines
5.3.7 Subunit Vaccines
5.3.8 Synthetic Vaccines
5.3.9 Y-o-Y Growth Analysis, By Vaccine Type
5.3.10 Market Attractiveness Analysis, By Vaccine Type
5.3.11 Market Share Analysis, By Vaccine Type
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Service Type
6.1.3.3 By Product Type
6.1.3.4 By Vaccine Type
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Service Type
6.1.4.3 By Product Type
6.1.4.4 By Vaccine Type
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Service Type
6.1.5.3 By Product Type
6.1.5.4 By Vaccine Type
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Bavarian Nordic A/S
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Thomas Jefferson University
8.3 Goodwin Biotechnology Inc.
8.4 BioMARK
8.5 Emergent BioSolutions
8.6 Soligenix Inc.
8.7 Catalent Biologics
8.8 Minneapolis Medical Research Foundation
8.9 FUJIFILM Diosynth Biotechnologies
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
